Get started
Author

Guillermo Sanz Santillana

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
2023 · Srdan Verstovsek, Aaron T Gerds, et al. · The Lancet · 202
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
2020 · Andreas Hochhaus, Carlo Gambacorti-Passerini, et al. · Leukemia · 84
PDF
Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
2021 · Gerald J. Gleich, Florence Roufosse, et al. · The Journal of Allergy and Clinical Immunology In Practice · 46
PDF
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
2022 · Marc E. Rothenberg, Florence Roufosse, et al. · The Journal of Allergy and Clinical Immunology In Practice · 23
PDF
MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
2023 · Guillermo Garcia-Manero, Kimo Bachiashvili, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
PDF
Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial
2025 · Rami S. Komrokji, Valeria Santini, et al. · British Journal of Haematology · 1
PDF
S173: Retrospective Study of Lenalidomide Discontinuation in Patients With Myelodysplastic Syndrome Harboring Del(5q). a Harmony Alliance Study
2023 · Elena Crisà, María Díez Campelo, et al. · HemaSphere · 1
Abstract CT060: Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
2024 · Guillermo Garcia-Manero, Bart L. Scott, et al. · Cancer Research
POSTER: MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
2023 · Guillermo Garcia-Manero, Kimo Bachiashvili, et al. · Clinical Lymphoma Myeloma & Leukemia
P719: Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-dose (ld) Oral Decitabine/cedazuridine (astx727) in Lower-risk Myelodysplastic Syndromes (lr-mds) Patients: Interim Safety Analysis
2023 · Guillermo Garcia-Manero, Kimo Bachishvili, et al. · HemaSphere
El trasplante de sangre de cordón umbilical: pasado, presente y futuro
2019 · Guillermo Sanz Santillana · Anales (Reial Acadèmia de Medicina de la Comunitat Valenciana)
What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools
2017 · A.M. Redondo Guijo, M. Sánchez-Barba, et al. · Leukemia Research
Works count: 12
Citation count: 360
H-index: 4
I10-index: 4
Year
Topic
Type